Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Structure And Functional Binding Epitope Of V-domain Ig Suppressor Of T-cell Activation (VISTA)
Nishant Mehta, Sainiteesh Maddineni, I. Mathews, Andres Parra Sperberg, Po-Ssu Huang, J. Cochran
Published 2019 · Chemistry, Biology
Save to my Library
Download PDFAnalyze on Scholarcy
V-domain Ig Suppressor of T cell Activation (VISTA) is an immune checkpoint protein that inhibits the T - cell response against cancer. Similar to PD-1 and CTLA-4, antibodies that block VISTA signaling can release the brakes of the immune system and promote tumor clearance. VISTA has an Ig-like fold, but little is known about its structure and mechanism of action. Here, we report a 1.85 Å crystal structure of the human VISTA extracellular domain and highlight structural features that make VISTA unique among B7 family members. Through fine-epitope mapping, we also identify solvent-exposed residues that underlie binding to a clinically relevant anti-VISTA antibody. This antibody-binding region is also shown to interact with V-set and Ig domain-containing 3 (VSIG3), the recently proposed functional binding partner of VISTA. The structure and functional epitope determined here will help guide future drug development efforts against this important checkpoint target.
This paper references
Mechanistic Assessment of PD-1H Coinhibitory Receptor–Induced T Cell Tolerance to Allogeneic Antigens
D. Flies (2015)
a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients
VISTA is an immune checkpoint molecule for human T cells.
J. L. Lines (2014)
Therapeutic role of the novel checkpoint regulator VISTA in murine autoimmune disease models. (P5174)
S. Ceeraz (2013)
A yeast surface display system for the discovery of ligands that trigger cell activation.
B. K. Cho (1998)
Construction of a versatile expression library for all human single-pass transmembrane proteins for receptor pairings by high throughput screening.
W. Yang (2017)
Structure-based cross-docking analysis of antibody–antigen interactions
K. P. Kilambi (2017)
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
L. Wang (2011)
Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients
H. Kakavand (2017)
Phenix - a comprehensive python-based system for macromolecular structure solution
P. Adams (2012)
Fine epitope mapping of anti-epidermal growth factor receptor antibodies through random mutagenesis and yeast surface display.
Ginger Chao (2004)
Phaser crystallographic software
A. McCoy (2007)
VISTA Regulates the Development of Protective Antitumor Immunity.
I. Le Mercier (2014)
Yeast surface display for antibody isolation: library construction, library screening, and affinity maturation.
James A Van Deventer (2014)
Monoclonal antibodies : methods and protocols
M. Albitar (2007)
Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer
M. Sznol (2013)
Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses
J. Liu (2015)
Anti vista antibodies and fragments
Modeling and docking of antibody structures with Rosetta
Brian D Weitzner (2017)
Coinhibitory receptor PD-1H preferentially suppresses CD4⁺ T cell-mediated immunity.
D. Flies (2014)
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
Jianjun Gao (2017)
Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains
H. Ogiso (2002)
Computer-Aided Drug Design Methods.
W. Yu (2017)
Dali server update
L. Holm (2016)
Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors
S. Xie (2018)
Lipidic cubic phases as matrices for membrane protein crystallization.
P. Nollert (2004)
The Role of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography in Well-Differentiated Neuroendocrine Tumors: A Case-Based Approach Illustrates Potential Benefits and Challenges.
N. Raj (2018)
Yeast surface display for directed evolution of protein expression, affinity, and stability.
E. Boder (2000)
VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML
L. Wang (2018)
Engineering antibody affinity by yeast surface display.
David W. Colby (2004)
Two-Stage PCR Protocol Allowing Introduction of Multiple Mutations , Deletions and Insertions Using QuikChange Site-Directed Mutagenesis
R GCGACCGAGTTGCTCTTGCCCC (1999)
VSIG‐3 as a ligand of VISTA inhibits human T‐cell function
J. Wang (2019)
Isolating and engineering human antibodies using yeast surface display
Ginger Chao (2006)
Miscellaneous algorithms for density modification.
K. Cowtan (1998)
A dimeric structure of PD-L1: functional units or evolutionary relics?
Y. Chen (2010)
Yeast surface display for screening combinatorial polypeptide libraries
E. Boder (1997)
High-resolution comparative modeling with RosettaCM.
Y. Song (2013)
The crystal structure of the extracellular domain of the inhibitor receptor expressed on myeloid cells IREM-1.
J. A. Márquez (2007)
The B7 family of immune-regulatory ligands
M. Collins (2005)
High-Density Infiltration of V-domain Immunoglobulin Suppressor of T-cell Activation Up-regulated Immune Cells in Human Pancreatic Cancer
Jinʼe Liu (2018)
Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non–Small Cell Lung Cancer
F. Villarroel‐Espíndola (2017)
Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant.
R. Pascolutti (2016)
VISTA expressed in tumour cells regulates T cell function
Kumuluzi Mulati (2018)
Two-stage PCR protocol allowing introduction of multiple mutations, deletions and insertions using QuikChange Site-Directed Mutagenesis.
W. Wang (1999)
This paper is referenced by
Considering B7-CD28 as a family through sequence and structure
S. West (2019)
VISTA: Coming of age as a multi‐lineage immune checkpoint
Mohamed A. ElTanbouly (2020)